KNOWN MEDICINE RAISES $7.2 MILLION SEED ROUND TO ADVANCE DATA FIRST APPROACH TO ORGANOID TECHNOLOGY

Known Medicine today announced the closure of its seed round of funding in the amount of $7.2 million led by Caffeinated Capital, with participation from Khosla Ventures, Cota Capital, Kickstart, Forward VC, OATV, Y Combinator and noted angel investors Chris Gibson, CEO & Co-Founder at Recursion Pharmaceuticals, Nish Bhat, previously Co-Founder at Color Genomics, and others. […]

Read More

Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelXTM Testing at Primary Care Level

Renalytix Plc announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion dollars for a population of 100,000 patients with type 2 diabetes (T2DKD) and chronic kidney disease tested with the Renalytix KidneyIntelX™ testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure. […]

Read More

Genomics 101 by Intermountain Precision Genomics

In a recent article published by Utah Business Magazine, Dr. Lincoln Nadauld, Chief of Precision Health at Intermountain Healthcare, provides an explanation of the genomic world and how precision medicine will be evolving in the future. Intermountain Precision Genomics, a BioUtah member, is located in St. George, Utah and is a world leader in genomics. […]

Read More